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Background: To investigate the short-term outcomes of treatment with intravitreal aflibercept in cases with wet
age-related macular degeneration (AMD) resistant to ranibizumab.
Methods: The study included patients who had been undergoing follow-up for a minimum of three months at the
Ankara University Faculty of Medicine Ophthalmology Department’s Retina Unit with a diagnosis of wet AMD. All
cases had received intravitreal aflibercept injection due to the presence of intraretinal/subretinal fluid and pigment
epithelial detachment (PED), as detected by optical coherence tomography (OCT), despite having received intravitreal
ranibizumab. Medical records of the cases were investigated retrospectively and the demographic data,
treatments administered before aflibercept injection, best-corrected visual acuity (BCVA) before and after aflibercept
injection, central macular thickness (CMT), and the presence of intraretinal/subretinal fluid and the height and presence
of PED were recorded.
Results: A total of 29 eyes from 11 females and 17 males were included in the study. The mean age was 73.89 ± 7.49
(62–92). The average number of intraocular injections administered before aflibercept injection was 11.75 ± 5.73 (6–25).
The mean duration of follow-up following aflibercept injection was 4.55 ± 2.14 (3–11) months, with a mean of 3.44 ± 0.73
(3–5) aflibercept injections during this period. The mean BCVA values before and after aflibercept injection were found to
be 0.83 and 0.77 LogMAR, respectively. The mean CMT values before and after aflibercept injection were 471.3 (97–1365)
and 345.1 (97–585) microns, respectively (p < 0.001). The PED height before and after aflibercept injection was 350.4 ±
151.7 (129–793) and 255.52 ± 156.8 (0–528) microns, respectively (p < 0.05).
Conclusion: Switching to intravitreal aflibercept appears to be an effective treatment modality for patients with AMD
who are resistant to ranibizumab. While anatomic success including the effect of reducing the PED height was achieved
in the short term following aflibercept injection in all cases, no concomitant increase in visual acuity occurred. This is
attributed to the long-term presence of chronic fluid and the development of scar tissue before the treatment.
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Multicenter trials have demonstrated the efficacy and
safety of vascular endothelial growth factor (VEGF) in-
hibitors in the treatment of wet age-related macular de-
generation (AMD) [1-8]. It has been reported that visual
acuity was maintained in 90% of the patients and there
was increased visual acuity in approximately 30% of the
patients receiving ranibizumab when it was administered
monthly or “as required” (pro re nata) [6-8]. Despite the
favorable results reported in multicenter studies, AMD* Correspondence: drsibeldemireltr@yahoo.com.tr
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unless otherwise stated.is a chronic disorder that requires continuous follow-up
and treatment. Based on the SEVEN-UP study reporting
the 7-year follow-up results of 65 wet AMD cases that
were receiving ranibizumab treatment and participated
in the ANCHOR, MARINA, and HORIZON studies,
50% of the patients required active treatment at the end
of the 7th year [9]. This may be the result of reactiva-
tions related to the natural course of the disease or due
to the occurrence of tachyphylaxis or tolerance to treat-
ment associated with long-term intravitreal drug use
[10,11]. In such cases, use of different treatment agents
is considered.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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that is composed of components of both VEGF receptor
1 (VEGFR1) and VEGF receptor 2 (VEGFR2) fused to
the Fc region of human IgG1. This molecule has a
higher affinity for binding to VEGF-A, a protein to
which ranibizumab and bevacizumab also bind, and it
also inhibits VEGF-B and placental growth factor
(PIGF) [12-16]. Based on the results from the VIEW 1
and 2 studies, aflibercept has been approved by the
FDA for treatment of wet AMD [17]. These multicen-
ter, randomized, double-blind studies have demon-
strated that anatomic and visual outcomes with 2 mg
aflibercept injections administered every 8 weeks following
a 3-month loading dose were comparable to those obtained
with monthly ranibizumab injections. Subsequently, it has
been put to use as a first choice of treatment or in cases re-
sistant to ranibizumab injection.
In this study, we assessed the short-term anatomic and
visual outcomes of intravitreal aflibercept in cases with
wet AMD resistant to intravitreal ranibizumab.
Methods
The study included patients who had been on long-term
ranibizumab for the treatment of wet AMD and had
switched to intravitreal aflibercept injection. Inclusion
criteria were as follows: persistent intraretinal or subret-
inal fluid with or without PED, at least six consecutive
monthly injections with ranibizumab, and last injection
of ranibizumab within 28–35 days of switching to afliber-
cept. The exclusion criteria included a history of intraocu-
lar surgery, except for uncomplicated phacoemulsification
performed within the preceding 6 months; history of sub-
foveal laser photocoagulation; uncontrolled glaucoma or
uveitis; and any ocular disease that could affect the BCVA
in the study eye. The study was conducted in accordance
with the Declaration of Helsinki and written informed
consent for participation in the study was obtained from
participants. The local ethics committee approval for hu-
man subjects research was received from Ankara Univer-
sity Medical Faculty with study protocol 20-848-14.
All patients received a loading dose of three monthly
aflibercept injections (2 mg/0.05 ml) and were followed
up monthly. Retreatment with a single aflibercept injec-
tion was performed according to any of the following:
visual acuity loss of at least five letters, with optical co-
herence tomography (OCT) evidence of fluid in the
macula; persistent or recurrent intraretinal or subretinal
fluid on OCT; new subretinal hemorrhage from chor-
oidal neovascularization (CNV).
Before and after aflibercept initiation, all patients
had a complete ophthalmic examination including
BCVA measurement, OCT, and fundus photography. Best-
corrected visual acuity was measured using the standard-
ized, 70-letter Early Treatment Diabetic Retinopathy Study(ETDRS) chart at 4 meters distance. Optical coherence
tomography images were obtained using the Spectralis
OCT (Spectralis Heidelberg Engineering, Heidelberg,
Germany) following a standardized protocol. The medical
records of patients with a minimum 3-month follow-up
duration since transition to aflibercept treatment were
retrospectively investigated. The demographic data, the
treatments administered before aflibercept injection, the
BCVA before and after aflibercept injection, the central
macular thickness (CMT), the presence of intraretinal/
subretinal fluid, and the height and presence of PED de-
tected by OCT were recorded. Changes in intraretinal/
subretinal fluid or PED height were described as complete/
partial resolution or stable/worsened, similar to descriptions
in previously published studies that discussed switching
anti-VEGF treatment [10,18]. In addition, potential side ef-
fects were investigated, including endophthalmitis following
injection, intraocular pressure increase requiring medical
treatment, retinal detachment, uveitis, and thromboembolic
events.
Results
The study included 29 eyes of 28 patients receiving in-
travitreal 2 mg/0.05 ml aflibercept injection for the treat-
ment of wet AMD resistant to intravitreal ranibizumab
injections. There were 11 females and 17 males with a
mean age of 73.89 ± 7.49 (62–92). The average number
of intra-ocular injections administered before aflibercept
injection was 11.75 ± 5.73 (6–25). Prior to ranibizumab
treatment, two cases received 2 and 4 intravitreal bevaci-
zumab injections, respectively, while another one case
was administered photodynamic therapy once and intra-
vitreal pegaptanib three times. All patients who switched
to aflibercept treatment had ongoing intraretinal and/or
subretinal fluid with or without PED despite previous
therapies. The mean duration of follow-up following afli-
bercept injection was 4.55 ± 2.14 (3–11) months, with
cases receiving an average of 3.44 ± 0.73 (3–5) aflibercept
injections during this period (Table 1).
The mean BCVA values before and after aflibercept in-
jection were 0.83 (44 ETDRS letters) and 0.77 LogMAR
(48 ETDRS letters), respectively. The mean CMT values
before and after aflibercept injection were 471.3 (97–1365)
and 345.1 (97–585) microns, respectively (p < 0.001). The
PED height before and after aflibercept injection was
350.4 ± 151.7 (129–793), and 255.52 ± 156.8 (0–528) mi-
crons, respectively (p < 0.05) (Table 1).
Before switching to aflibercept treatment, 5 eyes
(17.24%) had intraretinal/subretinal fluid and 24 eyes
(82.76%) had intraretinal/subretinal fluid and PED (22
fibrovascular, 2 serous). Following aflibercept injec-
tions, of the 29 eyes with intraretinal/subretinal fluid,
17 eyes (58.6%) had complete resolution, 10 eyes
(34.4%) had partial improvement, and 2 eyes (6.8%)
Table 1 Clinical characteristics of patients switched to
aflibercept from ranibizumab
Average number of intraocular injections
before
11.75±5.73 (6-25).
Aflibercept injection (average-interval) 3.44±0.73 (3-5)
BCVA values (average /logMAR-ETDRS letters)
Before aflibercept injection 1.08 (47.4 letters)
After aflibercept injection 0.80 (50 letters)
Central macular thickness (average-interval)
Before aflibercept injection 471.3 (97-1365)
After aflibercept injection 345.1 (97-585)
The mean height of PED
Before aflibercept injection 350.4 ± 151.7 (129-793)
After aflibercept injection 255.52 ± 156.8 (0-528)
BCVA: Best corrected visual acuity.
PED: Pigment epithelial detachment.
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with PED, 2 eyes (8.3%) (1 serous, 1 fibrovascular) had
complete resolution, 16 eyes (66.6%) had partial im-
provement of PED, 4 eyes (16.6%) remained stable,
while 2 cases (8.3%) had an increase in PED height
(Table 2) (Figures 1a–c, 2a,b). None of the patients
experienced any of the potential side effects that could
occur following intraocular injection, such as endophthal-
mitis, increased intraocular pressure requiring medical
treatment, retinal detachment, uveitis, or thromboembolic
events.
Discussion
Most patients with wet AMD require repeated intravit-
real injections in the long term [9]. This may be a result
of the ongoing activity of the disease or due to the oc-
currence of tachyphylaxis or tolerance to the medication.
Tachyphylaxis is the lack of response that occurs when a
drug is used at short intervals and no response can be
achieved upon dose escalation. However, when treat-
ment is interrupted for a short time, the efficacy of the
drug is regained [19]. In contrast, tolerance is a reduc-
tion in the extent and duration of a drug’s efficacy over
time as a result of long-term use. The efficacy of a drug
may be improved when the dose is increased or is ad-
ministered at shorter intervals. However, temporaryTable 2 Spectral-domain optical coherence tomography analy
SD-OCT segmentation Before aflibercept Complete res
Intraretinal/subretinal fluid 29 17
without PED 5 2
with PED 24 15
PED 24 2
SD-OCT: Spectral domain optic coherence tomography.
PED: Pigment epithelial detachment.interruption of the treatment does not lead to an im-
provement [19]. Development of tachyphylaxis in some
patients receiving repeated ranibizumab/bevacizumab
injections has been reported in several trials [10,11].
Gasperini et al. showed that 81% of the tachyphylactic
patients in their study responded favorably after switch-
ing from either ranibizumab to bevacizumab or vice
versa [10]. With systemic and local immune response
occurring in the cases following intravitreal injection,
neutralizing antibodies may develop against bevacizu-
mab/ranibizumab. In addition, several authors have sug-
gested that VEGF production could be upregulated via
macrophages in choroidal neovascular tissue due to
chronic VEGF blockage [11,20-22].
In the current study, we evaluated the functional and
anatomic response of patients with refractory neovascu-
lar AMD after conversion to aflibercept injection. The
lack of visual improvement in the eyes affected with re-
calcitrant neovascular AMD may be related to long-
standing retinal damage as a result of persistent
intraretinal and subretinal exudation. There is growing
evidence that resistant eyes respond well to different
anti-VEGF agents in some studies in which both func-
tional and anatomical improvement occurred within the
first few months. Aflibercept is a novel inhibitor that
provides an alternative VEGF blockage. After the efficacy
of intravitreal aflibercept in wet AMD cases was demon-
strated, it was introduced for use in patients who are re-
sistant to other anti-VEGF agents. The current relevant
studies are summarized in Table 3. These published
studies have reported anatomic improvement [18,23-28],
in particular. In one of these studies, Yonekawa et al. an-
alyzed the outcomes of 102 eyes of 96 patients with
chronic neovascular AMD and reported that replacing
ranibizumab with aflibercept in patients with chronic
neovascular AMD resulted in stabilized vision and im-
proved anatomic outcomes. After the switch, 91% of the
eyes with refractory AMD showed improvement in OCT
findings, while 9% were stable and no eyes worsened. In
line with these results, our study also particularly re-
vealed anatomic improvement following aflibercept in-
jections. According to OCT findings, among the 29 eyes
with baseline intraretinal/subretinal fluid, 17 (58.6%) had
complete resolution, 10 (34.4%) had partial resolution, 2sis before and after aflibercept injection





Figure 1 Good anatomical response to 3 aflibercept injections in a ranibizumab resistant AMD case. a. PED before intravitreal ranibizumab (VA:
0.8 LogMAR). b: Intense subretinal fluid is observed on OCT despite 24 ranibizumab injections (VA: 2.1 LogMAR). c. Subretinal fluid has completely
disappeared after a single aflibercept injection on OCT (VA: 2.1 LogMAR). d. No subretinal fluid is seen after the third aflibercept injection on OCT
(VA: 2.1 LogMAR)
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pre-treatment mean CMT value of 471.3 microns was
decreased to 345.1 microns after the treatment.
Various treatments of PED have been attempted; how-
ever, none has been demonstrated to be completelyFigure 2 Visual and anatomical improvement after 3 aflibercept injections
OCT following 11 ranibizumab injections (VA: 1.3 LogMAR). b: The cysts hav
LogMAR). c. There is no cyst on OCT and VA has been increased after the t
degeneration. PED: Pigment epithelial detachment. VA: Visual acuity. OCT: Oeffective. Recently, association of PED type and response
to anti-VEGF treatment were investigated [29,30]. Accord-
ing to Hoerster et al., fibrovascular PEDs were resistant to
treatment with ranibizumab, while serous PEDs responded
well [29]. Inoue et al. also revealed that 100% of serous andin a ranibizumab resistant AMD case. a. Large-septa cysts are seen on
e completely disappeared after a single aflibercept injection (VA: 0.7
hird aflibercept injection (VA:0.4 LogMAR). AMD: Age-related macular
ptic coherence tomography.
Table 3 Summary of the similar studies on aflibercept treatment in resistant AMD cases
Study group No of
eyes







Visual acuity (LogMAR) CMT (micron)
Before Afl After Afl Before Afl After Afl
Cho et al.1 28 80,68 (62-95) 20,2±7,6 (7-37) 4,4 (3-6) 171 (134–192) days 0,52 0,57 295 274
Bakall et al.2 36 79 (60-88) 25,6±(6-74) 5,2 (4-6) 6 0,45 0,50 410 (174-1027) 296 (151-528)




276 (130-559) 258 (198-242)
Yonekawa et al 4 102 79,6 (57-93) 20,4 (3-65) 3,8 (1-8) 18,4 weeks 0,42 0,38 305,07 276,20
Kumar et al 5 34 79 (72-84) 28,6 (10-47) 5,3 (5-6) 6,5 (6-6,6) 0,57 0,47 416±217 348±171
Hall et al 6 30 80,4 (-) 14,9 (2-53) 6,27 (4-11) 10,4 (3-12) 0,533* 0,521* 264±12,5* 237±10,2*
Heussen et al 7 71 77 (43-95) 9 (3-43) 2,7 (1-4) - 0,56+ 0,43+ 350.8±115+ 260.8±34+
*values of 22 eyes with 12 moths follow-up period.
+values of 45 eyes which had 3 aflibercept injections.
Afl: Aflibercept, CMT: Central macular thickness.
1Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013;97(8):1032-5.
2Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J
Ophthalmol. 2013;156(1):15-22.
3Ho VY, Yeh S,olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular
endothelial growth factor ınhibitors. Am J Ophthalmol. 2013;156(1):23-28.
4Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J
Ophthalmol. 2013;156(1):29-35.
5Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with
ranibizumab in patients with neovascular age-related macular degeneration. Retina 2012;33:1605–1612.
6Hall LB, Zebardast N, Huang JJ and Adelman RA. Aflibercept in the treatment of neovascular age-related Macular degeneration in previously treated patients. J Ocul
Pharmacol Ther. DOI: 10.1089/jop.2013.0188.
7Heussen FM, Shao Q, Ouyang Y et al. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular
degeneration. Graefes Arch Clin Exp Ophthalmol DOI 10.1007/s00417-013-2553-7.
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while this ratio was remained at 67% in fibrovascular PED
[30]. In the current study, there was a statistically significant
decrease in the mean PED height (from 350.4 to 255.52
microns, p < 0.05). While 16 of 24 (66.6%) eyes with PED
(15 fibrovascular 1 serous PED) showed partial improve-
ment in PED height, 2 (8.3%) eyes with PED (1 serous, 1
fibrovascular) showed complete resolution after aflibercept
treatment. There was a 27.05% decrease in the mean PED
height after switching to aflibercept treatment.
Basically, there are two mechanisms may be involved
in the improvement achieved in anatomic outcomes
with aflibercept in patients with wet AMD resistant to
other anti-VEGF treatments. One is the fact that this
molecule has a stronger and wider spectrum of effi-
cacy. While bevacizumab and ranibizumab are human
IgG1 isotypes, aflibercept is a monoclonal antibody
with a 100-fold higher VEGF-A binding affinity, which
is obtained by the integration of VEGF receptors 1
and 2, and IgG-1 crystalline fragments. In addition to
this high binding affinity, aflibercept also inhibits
other factors that affect neovascularization, such as
VEGF-B and placental growth factor [12-16]. The
second; studies suggest that patients treated with
repeated intravitreal injections of bevacizumab or
ranibizumab may have developed an immunity [10,11].
By switching to aflibercept, lesser immunogenicity as-
sociated with a new agent theoretically may lead to
sustained anatomic outcomes in eyes refractory toranibizumab [19]. In the similar studies, the anatom-
ical results exceed the functional results [18,23-28].
Heussen et al. analyzed the clinical outcomes of 71
eyes of 65 AMD patients after transition to aflibercept
treatment. They reported that 33% of cases with no
functional improvement under ranibizumab therapy
gained visual acuity after transition to aflibercept [28].
In the current study, before switching to aflibercept
treatment, eyes had persistent fluid despite 11.75
<?A3B2 twb.?>(6–25) intraocular ranibizumab injections
on average. The visual potential after switching to afliber-
cept might have been limited by the development of
chronic photoreceptor degeneration. Thus, visual im-
provement in addition to anatomic improvement may be
achieved by switching to aflibercept treatment earlier in
patients who are considered resistant to ranibizumab
treatment.Conclusions
The current study presents significant results on the effi-
cacy of aflibercept in the treatment of patients with wet
AMD resistant to ranibizumab. Intravitreal aflibercept
injections represent a strong alternative for treatment-
resistant cases. However, the retrospective design and
the limited number of cases constitute limitations of this
study. Larger case series need to be investigated pro-
spectively and with a long-term follow-up for more en-
lightened and long-term results to be obtained.
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